{"id":"NCT04939428","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-08-11","primaryCompletion":"2022-11-16","completion":"2022-11-16","firstPosted":"2021-06-25","resultsPosted":"2024-02-06","lastUpdate":"2024-09-26"},"enrollment":2441,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Coronavirus Disease (COVID-19)"],"interventions":[{"type":"DRUG","name":"Molnupiravir","otherNames":["MK-4482"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Molnupiravir","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; half of the study participants will receive molnupiravir twice daily by mouth and the other half will receive a placebo. The primary objectives of the study are to determine if molnupiravir prevents symptomatic COVID-19 disease and to evaluate its safety and tolerability. All participants who develop COVID-19 during the study are still eligible for any COVID-19 treatment recommended by their doctor.","primaryOutcome":{"measure":"Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14","timeFrame":"Day 14","effectByArm":[{"arm":"Molnupiravir","deltaMin":41,"sd":null},{"arm":"Placebo","deltaMin":54,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.0848"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":226,"countries":["United States","Argentina","Brazil","Bulgaria","Colombia","Dominican Republic","Egypt","France","Guatemala","Hungary","Japan","Kenya","Malaysia","Mexico","Peru","Philippines","Romania","Russia","South Africa","Spain","Thailand","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["37690669"],"seeAlso":["http://www.merckclinicaltrials.com","https://msd.trialsummaries.com/Study/StudyDetails?id=26072&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":763},"commonTop":[]}}